Role of extracellular ATP metabolism in regulation of platelet reactivity.
Extracellular adenosine triphosphate (ATP) regulates platelet reactivity by way of direct action on platelet purinergic receptors or by hydrolysis to adenosine diphosphate (ADP). Subsequent metabolism of ATP and ADP to adenosine monophosphate (AMP) and adenosine inhibits platelet aggregation. Endothelial cell membrane-bound ecto-ATP/ADPase (CD39, E-NTPDase1) is thought to be the main regulator of platelet responsiveness. However, the findings in studies of CD39-knockout mice imply that nucleotidase(s) in plasma regulates circulating adenine nucleotides levels. Understanding extracellular ATP metabolism by CD39 and plasma nucleotidases is therefore important. In this study, alpha-phosphorus 32- and gamma-phosphorus 32-labeled ATP were rapidly metabolized directly to AMP and pyrophosphate in human plasma at pH 7.4, suggesting the presence of pyrophosphatase/phosphodiesterase-like activity. A specific phosphodiesterase substrate, p-nitrophenol-5'-TMP (p-Nph-5'-TMP), was readily hydrolyzed in human plasma. The antiaggregatory action of beta,gamma-methylene-ATP (AMPPCP) (5 micromol/L) was blocked by DMPX, an adenosine-receptor antagonist, suggesting that in plasma, AMPPCP was metabolized to AMP and adenosine. Recombinant soluble CD39 (solCD39) was used to assess the role of CD39 in ATP metabolism. As little as 0.25 microg/mL of solCD39 inhibited ADP-induced platelet aggregation. However, in the presence of ADP-free ATP (10 micromol/L), solCD39 induced platelet aggregation in a dose-dependent manner. Because AMPPCP could not substitute for ATP in solCD39-stimulated platelet aggregation, it is likely that ADP formation from ATP was required. Endogenous CD39 may thus have a hemostatic function by promoting ADP formation from released ATP, in addition to its antiaggregatory properties. A plasma nucleotidase hydrolyzes ATP directly to AMP. This prevents ADP accumulation and generates adenosine, a potent, locally acting inhibitor of platelet reactivity. The presence of both endothelial CD39 and plasma nucleotidase appears to be important in the maintenance of normal hemostasis and prevention of excessive platelet responsiveness.
Birk
Alex V
AV
Department of Pharmacology, Weill Medical College of Cornell University, New York, NY 10021, USA.
Broekman
M Johan
MJ
Gladek
Eva M
EM
Robertson
Hugh D
HD
Drosopoulos
Joan H F
JH
Marcus
Aaron J
AJ
Szeto
Hazel H
HH
D000244:Adenosine Diphosphate / Q000032:analysis / Q000378:metabolism; D000251:Adenosine Triphosphatases / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives* / Q000032:analysis / Q000378:metabolism* / Q000494:pharmacology; D015703:Antigens, CD / Q000494:pharmacology; D001081:Apyrase; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004336:Drug Antagonism; D006801:Humans; D006868:Hydrolysis; D066298:In Vitro Techniques; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D010761:Phosphorus Radioisotopes; D010974:Platelet Aggregation / Q000187:drug effects; D013805:Theobromine / Q000031:analogs & derivatives* / Q000494:pharmacology
D015703:Antigens, CD; D010761:Phosphorus Radioisotopes; C005147:5'-adenylyl (beta,gamma-methylene)diphosphonate; C057837:3,7-dimethyl-1-propargylxanthine; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D010727:Phosphoric Diester Hydrolases; D000251:Adenosine Triphosphatases; D001081:Apyrase; C067869:CD39 antigen; D013805:Theobromine